Outcome of SARS-CoV-2 infection among patients with common variable immunodeficiency and a matched control group: A Danish nationwide cohort study.
clinical outcome
common variable immunodeficiency (CVID)
inborn errors of immunity (IEI)
severe adult respiratory coronavirus-2 (SARS-CoV-2)
severe novel coronavirus 2019 (COVID-19)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
07
2022
accepted:
31
08
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
The risk of severe adult respiratory coronavirus-2 (SARS-CoV-2) infection and the course of the infection among individuals with common variable immunodeficiency (CVID) relative to the general population have been a matter of debate. We conducted a Danish nationwide study comparing the timing of SARS-CoV-2 vaccination, the risk of first confirmed SARS-CoV-2 infection, re-infection, and the outcome of infection among individuals with CVID relative to an age- and gender matched control group. Cox regression was used to calculate incidence rate ratios. The CVID patients received SARS-CoV-2 vaccinations earlier than those included in the population control group. Even so, the risks of both first infection and re-infection were increased among the individuals with CVID. The CVID group also had increased risk for hospital contacts due to SARS-CoV-2 infection relative to the general population. However, reassuringly, the risk of mechanical ventilation and death did not differ between the groups, but the numbers were low in both groups, making the estimates uncertain. Though this is the largest study to investigate the risk of SARS-CoV-2 infections and outcomes hereof among individuals with CVID relative to the general population, we cannot rule out minor differences in severity, which might only be detectable with an even larger sample size.
Identifiants
pubmed: 36211430
doi: 10.3389/fimmu.2022.994253
pmc: PMC9539828
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
994253Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Katzenstein, Rasmussen, Drabe, Larsen, Hansen, Stærkind, Knudsen, Hansen and Obel.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Immunol. 2021 Oct;41(7):1479-1489
pubmed: 34164762
J Allergy Clin Immunol Pract. 2020 Nov - Dec;8(10):3594-3596.e3
pubmed: 32947026
Clin Infect Dis. 2022 Dec 19;75(12):2161-2168
pubmed: 35511586
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119
pubmed: 35576468
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2904-2906.e2
pubmed: 33894392
Pediatr Allergy Immunol. 2022 Jan;33(1):e13661
pubmed: 34510555
J Allergy Clin Immunol. 2021 Feb;147(2):520-531
pubmed: 32980424
Allergy. 2022 Jan;77(1):282-295
pubmed: 34314546
Front Immunol. 2021 Jan 14;11:614086
pubmed: 33519822
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
J Clin Epidemiol. 2004 Dec;57(12):1288-94
pubmed: 15617955
J Clin Immunol. 2021 Feb;41(2):345-355
pubmed: 33263173
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
J Clin Immunol. 2022 Jul;42(5):935-946
pubmed: 35445287
Euro Surveill. 2022 Mar;27(10):
pubmed: 35272746
Lancet Infect Dis. 2022 Jul;22(7):942-943
pubmed: 35690075
Am J Clin Exp Immunol. 2021 Oct 15;10(3):77-85
pubmed: 34824897
Front Immunol. 2022 Feb 28;13:835770
pubmed: 35296097
J Allergy Clin Immunol Pract. 2021 Jan;9(1):504-507.e1
pubmed: 33217615
Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):515-524
pubmed: 34494617
Front Immunol. 2019 Dec 10;10:2753
pubmed: 31921101
Infect Dis (Lond). 2021 Nov-Dec;53(12):953-958
pubmed: 34375571
Am J Transplant. 2022 Nov;22(11):2627-2636
pubmed: 35801493
J Allergy Clin Immunol. 2020 Jul;146(1):211-213.e4
pubmed: 32333914
C R Biol. 2021 Jun 21;344(1):19-25
pubmed: 34213846
J Allergy Clin Immunol. 2021 Mar;147(3):870-875.e1
pubmed: 33338534
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
Clin Infect Dis. 2022 Aug 24;75(1):e579-e584
pubmed: 35245940
Sci Rep. 2021 Jul 27;11(1):15278
pubmed: 34315958
Ugeskr Laeger. 2018 Feb 26;180(9):
pubmed: 29506644
J Interferon Cytokine Res. 2020 Dec;40(12):549-554
pubmed: 33337932
Cureus. 2022 Mar 12;14(3):e23094
pubmed: 35464498
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Front Med (Lausanne). 2020 Apr 30;7:190
pubmed: 32426363
Curr Opin Allergy Clin Immunol. 2021 Dec 1;21(6):535-544
pubmed: 34580250
Scand J Immunol. 2017 Jun;85(6):450-461
pubmed: 28370285
J Clin Immunol. 2021 Oct;41(7):1463-1478
pubmed: 34114122
Dan Med Bull. 2006 Nov;53(4):441-9
pubmed: 17150149
PLoS Med. 2021 Dec 17;18(12):e1003874
pubmed: 34919548
J Clin Immunol. 2021 Oct;41(7):1515-1522
pubmed: 34231093